Skip to content
S6332Senate2023-2024 SessionSame asA62

Require Abuse-Deterrent Opioids

Official title

“Limits the substitution of abuse-deterrent analgesic opioid drug products for analgesic opioids lacking such technology”

Sponsor Samra BroukSD-55Affects Health
Status
In Senate Committee
Health
Impact
7/10
Significant
Passage
0%

Bill progress

Step 2 of 7

In committee · Health

What's happening

This bill requires insurance coverage and limits cost-sharing for opioid drugs with abuse-deterrent properties, aiming to reduce opioid abuse and diversion.

Why it matters

  1. Ensures patients and prescribers cannot be forced to try non-abuse-deterrent opioids first. removing a common insurance hurdle that delays access to safer formulations and may reduce initial exposure to higher-risk drugs.

  2. Requires insurers to cover at least one abuse-deterrent opioid per active ingredient. broadening patient access to these safer alternatives across a wide range of opioid medications.

  3. Limits out-of-pocket costs for abuse-deterrent opioids. mandating that patient cost-sharing for these drugs can be no higher than for equivalent non-abuse-deterrent versions, which helps prevent financial barriers to safer pain management options.

  4. Prohibits insurers from shifting costs or creating disincentives for prescribers. ensuring that compliance with this law cannot be achieved by increasing patient expenses or penalizing healthcare providers, thus supporting more widespread and equitable adoption of abuse-deterrent opioids.

The daily · weekday mornings

Albany, before your first meeting.

Every bill that moved yesterday, summarized in a sentence and ranked by impact. The Albany Scorecard follows on Sundays.

Free. Unsubscribe in one click. Want alerts on specific bills? Create an account.

Headline styles

Require Abuse-Deterrent Opioids

Plain English, a few words. Used as the page title.

Sponsors

Primary sponsor
Samra Brouk

Senator · Senate District 55

Chair, Mental Health

No co-sponsors yet.

History

  1. Referred to health
  2. Referred to health

Companion bill

The same bill in the other chamber. A bill becomes law when one version passes both houses and the governor signs it, so either number can carry it.

A62Assembly

Prioritize Abuse-Deterrent Opioids

In Assembly Committee · Insurance · Sponsor Nader Sayegh

Impact 7 · Significant0% to pass

Full text

2 pagesUnderlined is new[Struck] is removedOfficial text on nysenate.gov ↗

STATE OF NEW YORK

6332

2023-2024 Regular Sessions

IN SENATE

April 14, 2023

Introduced by Sen. BROUK -- read twice and ordered printed, and when printed to be committed to the Committee on Health

AN ACT to amend the public health law and the insurance law, in relation to the use of abuse-deterrent technology for opioids as a mechanism for reducing abuse and diversion of opioid drugs

The People of the State of New York, represented in Senate and Assembly, do enact as follows:

Section 1. Section 273 of the public health law is amended by adding a new subdivision 11 to read as follows:

11. Any prior authorization requirements for opioid analgesic and any service denials made pursuant thereto shall not require use of opioid analgesic drug products without abuse-deterrent properties before authorizing the use of abuse-deterrent opioid analgesic drug products.

§ 2. The insurance law is amended by adding a new section 3216-a to read as follows:

§ 3216-a. Access to abuse-deterrent opioid medications. (a) An insurance carrier or health plan shall provide coverage on its formulary, drug list or other lists of similar construct for at least one abusedeterrent opioid analgesics drug product per opioid analgesics active ingredient.

(1) Cost-sharing for brand name abuse-deterrent opioid analgesic drug products covered pursuant to this section shall not exceed the lowest cost-sharing level applied to brand name non-abuse deterrent opioid drugs covered under the applicable health plan or policy.

(2) Cost-sharing for generic abuse-deterrent opioid analgesic drug products covered pursuant to this section shall not exceed the lowest cost-sharing level applied to generic non-abuse deterrent opioid drugs covered under the applicable health plan or policy.

(3) An increase in patient cost-sharing or disincentives for prescribers or dispensers shall not be allowed to achieve compliance with this section.

EXPLANATION--Matter in italics (underscored) is new; matter in brackets

[ ] is old law to be omitted.

LBD01769-01-3

(b) Any prior-authorization requirements or other utilization review measures for opioid analgesics, and any service denials made pursuant thereto, shall not require use of opioid analgesic drug products without abuse-deterrent properties in order to access abuse-deterrent opioid analgesic drug products.

(c) Definitions. As used in this section:

(1) "Opioid analgesic drug product" means a drug in the opioid analgesic drug class prescribed to treat moderate to severe pain or other conditions, whether in immediate release or extended long acting release form and whether or not combined with other drug substances to form a single drug product or other dosage form.

(2) "Abuse deterrent opioid analgesic drug product" means a brand or generic opioid analgesic drug product approved by the federal food and drug administration with abuse-deterrence labeling claims indicating its abuse-deterrent properties are expected to deter or reduce its abuse.

(3) "Cost-sharing" means any coverage limit, copayment, coinsurance, deductible or other out-of-pocket patient expense requirements.

§ 3. This act shall take effect on the one hundred twentieth day after it shall have become a law, and shall apply to all policies and contracts issued, renewed, modified, altered or amended on or after such date.

Reflowed for reading: line numbers and page breaks removed. Cite the official text.

Sponsor's memo

Title of bill

An act to amend the public health law and the insurance law, in relation to the use of abuse-deterrent technology for opioids as a mechanism for reducing abuse and diversion of opioid drugs

Purpose

To help prevent the abuse and diversion of opioid analgesic drugs by ensuring that abuse-deterrent drugs approved by the FDA are accessible to patients and that that insurance coverage does not disadvantage. access for patients to drugs approved by the FDA as abuse-deterrent.

Summary of provisions

Section 1 adds a new subdivision 11 to section 273 of the public health law to ensure patient access to abuse-deterrent opioid analgesic drugs by requiring that a minimum of one opioid abuse-deterrent opioid anal- gesic drug per opioid analgesic active ingredient is covered by insur- ance plans and to ensure that a patient is not required to take a non-a- buse deterrent opioid before an abuse-deterrent opioid version.

Section 2 adds a new section 3216-a to the insurance law to ensure patient access to abuse-deterrent opioid analgesic drugs by requiring that a minimum of one opioid abuse-deterrent opioid analgesic drug per opioid analgesic active ingredient is covered by insurance plans and to ensure that a patient is not required to take a non-abuse deterrent opioid before an abuse-deterrent opioid version.

Section 3 sets the effective date.

Justification

Abuse deterrent formulations (ADFs) represent a breakthrough technology that helps prevent the crushing, snorting, and injection of painkillers. Currently, many prescription drug plans present access barriers for chronic pain patients to ADFs including cost-sharing tiers, fail-first requirements, and prior authorization requirements. Instead of receiving ADFs, often patients are limited to using traditional opioids that can be easily diverted, crushed, snorted, and injected. The U.S. Food and Drug Administration (FDA)is encouraging the development of prescription opioids with abuse-deterrent formulations to help combat the opioid crisis. The agency recognizes that abuse-deterrent opioids are not abuse- or addiction-proof but are a step toward products that may help reduce abuse. According to the FDA, "abuse-deterrent formulations target the known or expected routes of abuse, such as crushing in order to snort or dissolving in order to inject, for the specific opioid drug substance. The science of abuse deterrence is relatively new, and both the formulation technologies and the analytical, clinical, and statis- tical methods for evaluating those technologies are rapidly evolving."

Legislative history

2021-22: S4532 - Passed Senate;A4667 - Referred to Insurance.

Fiscal implications

None.

Effective date

This act shall take effect on the 120th day after it shall have become a law, and shall apply to all policies and contracts issues, renewed, modified, altered or amended on or after such date.

Summaries, headlines and scores are AI-generated from the official bill text. How we score bills. Source: NYS Open Legislation.